Posted 13 November, 2023
CARGO Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:CRGX in a 424B4 filed on 13 November, 2023.
This is an initial public offering of shares of common stock of CARGO Therapeutics, Inc.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of CARGO Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.Market Cap
$180M
View Company Details
$180M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.